# Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

> **NCT02077933** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 79 (actual)

## Conditions studied

- Neoplasms
- Breast Neoplasms
- Kidney Neoplasms
- Pancreatic Neuroendocine Neoplasms (pNETs)

## Interventions

- **DRUG:** alpelisib
- **DRUG:** everolimus
- **DRUG:** exemestane

## Key facts

- **NCT ID:** NCT02077933
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-14
- **Primary completion:** 2019-04-12
- **Final completion:** 2019-04-12
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077933, "Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02077933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*